Nursing and Health Professions
Cost Effectiveness Analysis
100%
Health Care Cost
67%
Quality Adjusted Life Year
50%
Vacuum Assisted Closure
46%
Cost Utility Analysis
35%
Economic Evaluation
31%
Cesarean Section
30%
Telehealth
30%
Case Mix
30%
Rheumatoid Arthritis
30%
Inflammatory Arthritis
30%
Quality of Life
28%
Disease
27%
Surgical Infection
23%
Cerebral Palsy
21%
Health Service
21%
Cost Control
20%
Hospital Setting
20%
Body Mass
19%
Heart Rehabilitation
17%
Incremental Cost-Effectiveness Ratio
17%
Patient-Reported Outcome
17%
Hospital Cost
16%
Pilot Study
15%
Ischemic Heart Disease
15%
Cancer Therapy
15%
Primary Medical Care
15%
Traumatic Brain Injury
15%
Mood Disorder
15%
Brain Ischemia
15%
Vascular Surgery
15%
Respite Care
15%
Palliative Therapy
15%
Predictive Validity
15%
Anxiety Disorder
15%
Frailty
15%
Neuroprotection
15%
Intimate Partner Violence
15%
Heart Disease
15%
Magnesium Sulfate
15%
Systematic Review
15%
Meta Analysis
15%
Cognitive Remediation Therapy
15%
Risk Behavior
15%
Cerebrovascular Accident
15%
Injury
13%
Hospital Readmission
12%
Hospital Department
12%
Premature Labor
10%
Seroma
10%
Medicine and Dentistry
Negative Pressure Wound Therapy
61%
Health Care Cost
59%
Cost-Effectiveness Analysis
51%
Randomized Clinical Trial
33%
Cesarean Section
30%
Meta-Analysis
30%
Drug Therapy
30%
Randomized Controlled Trial
23%
Seroma
20%
Surgical Incision
20%
Heart Rehabilitation
20%
Comorbidity
20%
Surgical Infection
19%
Systematic Review
17%
Ischemic Heart Disease
17%
Coronary Artery Bypass Graft
17%
Health Care
17%
Acquired Brain Injury
15%
Cancer Therapy
15%
Emergency Department
15%
Neuroprotection
15%
Coronary Artery Disease
15%
Respite Care
15%
Somatics
15%
Frailty
15%
Off-Label Use
15%
Symptomatic Treatment
15%
Cohort Analysis
15%
Magnesium Sulfate
15%
Polypharmacy
15%
Sequela
15%
Minimal Effective Dose
15%
Nutrition
15%
Adolescence
15%
Quality of Life
12%
Quality Adjusted Life Year
12%
Body Mass Index
11%
Premature Labor
10%
General Practitioner
10%
Instrumental Variable Analysis
10%
Infection
10%
Wound Infection
10%
Wound Complication
10%
Diagnosis
9%
Glomerular Filtration Rate
9%
Health System
8%
Risk-Benefit Ratio
7%
Incision
7%
EuroSCORE
7%
Observational Study
7%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
33%
Coronavirinae
30%
Antipsychotic
30%
Off-Label Use
21%
Cohort Study
18%
Typical Antipsychotic
16%
Ischemic Heart Disease
15%
Magnesium Sulfate
15%
Randomized Controlled Trial
15%
Ethanol
15%
Minimal Effective Dose
15%
Comorbidity
15%
Frailty
15%
Neuroprotection
15%
Premature Labor
10%
Risk Evaluation
10%
Prevalence
8%
Polypharmacy
7%
Adverse Event
6%
Cerebral Palsy
6%
